Merck's rotavirus vaccine RotaTeq was recommended for use by the Centers for Disease Control & Prevention's Advisory Committee on Immunization Practices Feb. 21. The committee voted 12-0 with two abstentions for routine immunization of infants with three doses of the oral vaccine to be administered at two, four and six months of age. CDC analysis found that RotaTeq was not cost effective at the published price of $62 per dose, but could be cost effective at $42 per dose. RotaTeq was approved in early February (1"The Pink Sheet" Feb. 12, 2006, p. 25)...
You may also be interested in...
Merck will begin a targeted disease awareness print and internet advertising campaign this spring as part of the launch of the rotavirus vaccine RotaTeq
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.